One hundred μL of whole blood was incubated for 30 min at room temperature with optimized doses and combinations of the following anti-human antibodies:
anti-CD3-PerCP (SK7, BD, San Jose, CA) or
anti-CD3-Alexa Fluor 700 (UCHT1, Thermo Fisher, Waltham, MA, USA),
anti-CD8-PE (RPA-T8; BD) or anti-CD8-Alexa Fluor 700 (OKT8; Thermo Fisher), anti-CD4-APC-eFluor 780 (RPA-T4, Thermo Fisher), anti-HLA-DR-FITC or APC-eFluor 780 (LN3, Thermo Fisher), anti-CD38-PE Cy7 or PE-eFluor 610 (HIT2, Thermo Fisher), anti-PD-1-PerCP-eFluor 710 (F38-2E2, Thermo Fisher), anti-CCR7-PE (3D12, Thermo Fisher),
anti-CD45RO-PE (UCHL1, BD),
anti-CD45RA-PE Cy7 (HI100, BD),
anti-CD28-PE (L293, BD), anti-CD57-FITC (TB01, Thermo Fisher), anti-CD95-FITC (DX2, BD) and anti-CD152-PE (BNI3, BD Pharmingen). Next, red blood cells were removed with 1X
FACS Lysing Solution (BD) during 20 min at room temperature, followed by a washing step with 1 mL of 1X PBS and fixation in 1% paraformaldehyde. The cells were acquired on a
LSR Fortessa cytometer (BD), using the FACS Diva software v. 6.0, within one hour of completing the staining; at least 50,000 CD3
+ events were acquired. Data were analyzed with the FlowJo Software version 10.4 (Tree Star, Inc, Ashland, OR, USA). Fluorescence minus one control was included to define positive thresholds.
Perdomo-Celis F., Velilla P.A., Taborda N.A, & Rugeles M.T. (2019). An altered cytotoxic program of CD8+ T-cells in HIV-infected patients despite HAART-induced viral suppression. PLoS ONE, 14(1), e0210540.